SCHEMBL6893747

SCHEMBL6893747

Cc1ccc(C(=O)OCI)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.57
RAB9A P51151 4/20 0.56
ALDH1A1 P00352 4/20 0.56
NPC1 O15118 2/20 0.56
MAPT P10636 2/20 0.56
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
ESR1 P03372 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
ESR2 Q92731 1/20 0.52
CA14 Q9ULX7 1/20 0.52
GAA P10253 1/20 0.51
KMT2A Q03164 1/20 0.51
LMNA P02545 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAOA P21397 1/20 0.50
ADRB2 P07550 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8678581 0.85 TDP1 (0.59) TDP1RAB9AALDH1A1NPC1MAPT
SCHEMBL206554 0.83 TDP1 (0.61) TDP1RAB9AALDH1A1NPC1MAPT
SCHEMBL1688854 0.83 TDP1 (0.61) TDP1RAB9AALDH1A1NPC1MAPT
SCHEMBL235800 0.83 CA2 (0.73) TDP1RAB9AALDH1A1NPC1MAPT
SCHEMBL8680535 0.81 TDP1 (0.59) TDP1RAB9AALDH1A1NPC1MAPT
Hydrochloric Acid SCHEMBL28242785 0.81 CA2 (0.70) TDP1RAB9AALDH1A1NPC1MAPT
SCHEMBL28816340 0.80 TDP1 (0.55) TDP1RAB9AALDH1A1NPC1MAPT
SCHEMBL6578044 0.79 TDP1 (0.64) TDP1RAB9AALDH1A1NPC1MAPT
SCHEMBL555991 0.79 KMT2A (0.51) RAB9AALDH1A1NPC1MAPTCA1
SCHEMBL8742866 0.79 TDP1 (0.57) TDP1RAB9AALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 TDP1 3544/4885RAB9A 1538/4885ALDH1A1 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.